Wednesday, June 24, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 893 of 1,261

  1. US 8337830

    Yeast-based vaccines as immunotherapy

    The Regents of the University of Colorado · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  2. US 8337848

    Monoclonal antibody for APP

    University College Cardiff Consultants Limited · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  3. US 8338624

    Isoflavone derivatives and uses thereof

    Medical Research and Infrastructure Fund of Tel-Aviv Sourasky Medical Center · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  4. US 8337815

    Pulmonary surfactant formulations

    Discovery Laboratories, Inc. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  5. US 8337839

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  6. US 8338462

    1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors

    Takeda Pharmaceutical Company Limited · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  7. US 8338424

    Guanidine-containing compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  8. US 8338107

    Method for producing polymers having a preselected activity

    CATALYST ASSETS, LLC · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  9. US 8338104

    Method of diagnosing poor survival prognosis colon cancer using miR-103-2

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  10. US 8338102

    Method of diagnosing poor survival prognosis colon cancer using miR-181b

    The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  11. US 8337896

    Drug-containing nanoparticles

    Takeda Pharmaceutical Company Limited · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  12. US 8338135

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  13. US 8338412

    Inhibitors of P38

    Vertex Pharmaceuticals Incorporated · Granted Dec 25, 2012 · Expires Dec 20, 2032

    granted

  14. US 8333959

    Ex-vivo application of solid microparticulate therapeutic agents

    Board of Regents of the University of Nebraska by and behalf of the University of Nebraska Medical Center · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  15. US 8334373

    Nuclease resistant double-stranded ribonucleic acid

    Alnylam Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  16. US 8334282

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  17. US 8334239

    High affinity VEGF-receptor antagonists

    The Board of Regents of the University of Texas System · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  18. US 8334297

    2,4-pyrimidinediamine compounds for treatment of inflammatory disorders

    Rigel Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  19. US 8334259

    Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative

    The Board of Regents of the University of Texas System · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  20. US 8334377

    Porphyrin catalysts and methods of use thereof

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  21. US 8334409

    Process for purifying rasagiline base

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  22. US 8334313

    Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  23. US 8334301

    5-Membered heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

  24. US 8334296

    2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Dec 18, 2012 · Expires Dec 13, 2032

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.